{"entity":{"id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","aka":[],"tldr":"A phase 1/2 trial of Aldesleukin, Avelumab, Nivolumab in metastatic cancer and melanoma, run by Aulos Bioscience, Inc., now recruiting.","summary":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05267626 by Aulos Bioscience, Inc., with 159 participants planned, started 2022-04-04 and due to reach its primary completion in 2027-02-28. Interventions recorded: AU-007, Aldesleukin, Avelumab, Nivolumab. Conditions listed: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05267626","url":"https://clinicaltrials.gov/study/NCT05267626"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","melanoma","nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["aldesleukin","avelumab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05267626","phase":"1/2","setting":"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","sponsor":"Aulos Bioscience, Inc.","enrolled":159,"outcomes":[]},"route":"/trials/nct05267626/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/"},{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}]}}